Therefore, treatment with BCL-2 inhibitors targets a direct pathway of the MLL/AF4 driver mutation, indicating that this could be a specific vulnerability of these poor-prognosis t(4;11) leukemias. This evidence concerns the gene BCL2 and leukemia.